Bronchiolitis+1
RecruitingStudy of nirsevimab and RSV vaccine (Abrysvo) for prevention of respiratory syncytial virus infection in infants during their first year of life
Study of nirsevimab and RSV vaccine (Abrysvo) for prevention of respiratory syncytial virus infection in infants during their first year of life
- Disease:BronchiolitisRespiratory syncytial virus infection
- Substances:NirsevimabRESPIRATORY SYNCYTIAL VIRUS, SUBGROUP A, STABILIZED PREFUSION F PROTEIN 847A
France- Participants:0–17 years · 18–64 years
- Substances:Nirsevimab
- Sponsor:Centre Hospitalier Annecy Genevois
